UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 14A

(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrant [X] Filed by a Party other than the Registrant []

Check the appropriate box:

[] Preliminary Proxy Statement

[] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

[] Definitive Proxy Statement

[X] Definitive Additional Materials

[] Soliciting Material Pursuant to §240.14a-12

BioTime, Inc.

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

[X] No fee required.

[] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

(1) Title of each class of securities to which transaction applies:

(2) Aggregate number of securities to which transaction applies:

- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
- (4) Proposed maximum aggregate value of transaction:

(5) Total fee paid:

[] Fee paid previously with preliminary materials.

- [] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.
- (1) Amount previously paid:
- (2) Form, schedule or registration statement no.:

(3) Filing party:

(4) Date filed:

*** Exercise Your *Right* to Vote *** Important Notice Regarding the Availability of Proxy Materials for the Shareholder Meeting to Be Held on July 30, 2019

BIOTIME, II	C. Meeting Information Meeting Type: Annual Meeting For holders as of: June 10, 2019 Date: July 30, 2019 Time: 7:30 AM PDT Location: BioTime. Inc. 1010 Atlantic Avenue Suite 102 Alameda, CA 94501
BIOTIME, INC. ATTM: Chase Leavitt 1010 Atlantic Avenue Suite 102 Alameda, DA 94501	You are receiving this communication because you hold shares in the above named company. This is not a ballot. You cannot use this notice to vote these shares. This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. You may view the proxy materials online at www.proxyvote.com or easily request a paper copy (see reverse side).
	We encourage you to access and review all of the important information contained in the proxy materials before voting.
	See the reverse side of this notice to obtain proxy materials and voting instructions.

– Before You Vote —

How to Access the Proxy Materials



- How To Vote -

Please Choose One of the Following Voting Methods

Vote In Person: Many shareholder meetings have attendance requirements including, but not limited to, the possession of an attendance ticket issued by the entity holding the meeting. Please check the meeting materials for any special requirements for meeting attendance. At the meeting, you will need to request a ballot to vote these shares.

Vote By Internet: To vote now by Internet, go to www.proxyvote.com. Have the information that is printed in the box marked by the arrow \rightarrow [xxxx xxxx xxxx xxxx] available and follow the instructions.

Vote By Mail: You can vote by mail by requesting a paper copy of the materials, which will include a proxy card.

	Voting ite	ems			
	Board of Directors re the following nominee				
1.	Election of Directors				
	Nominees				
	Deborah Andrews Alfred D. Kingsley	1b. Don Bailey 1g. Michael H. Mulroy	1c. Neal C. Bradsher 1h. Angus C. Russell	1d. Brian M. Culley	1e. Stephen C. Farrell
The	Board of Directors re	commends you vote FOR propos	als 2, 3 and 4		
2.	To ratify the appoint the fiscal year ending		Company's independent regi	stered public accounting firm	n for

- 3. To approve, on an advisory basis, compensation paid to the Company's named executive officers
- 4. To amend the Company's 2012 Equity Incentive Plan to increase the number of common shares authorized for issuance thereunder from 16,000,000 to 24,000,000

NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

0000425630_4 R1.0.1.18